tldrdailynews.com logo
Tag

Roche

All articles tagged with #roche

Roche bets on tri-specific B-cell therapy in $1.53B licensing deal
business3 days ago

Roche bets on tri-specific B-cell therapy in $1.53B licensing deal

Roche agreed to pay $75 million upfront and up to $1.53 billion in total payments for exclusive global rights to SIM0660, a preclinical trispecific antibody targeting CD79a, CD19 and CD3 designed to recruit T cells against B-cell–mediated diseases while aiming to limit cytokine release. The deal broadens Roche’s licensing activity and continues Simcere Zaiming’s pattern of biobucks-driven partnerships, with the asset potentially relevant for patients who have received CD20/CD19-directed therapies and for autoimmune conditions.

via Fierce Biotech|
#b-cell-diseases#business#roche
FDA clears Alzheimer's blood test to flag brain changes earlier
health9 days ago

FDA clears Alzheimer's blood test to flag brain changes earlier

The FDA has cleared Roche and Eli Lilly’s Elecsys pTau217 blood test to help identify Alzheimer’s disease–related brain changes in people 55 and older with cognitive decline; the biomarker test can run on more than 4,500 Roche analyzers in the United States and is intended to aid, not replace, diagnosis when used with other clinical information. European approval followed in May, and Labcorp and Quest Diagnostics plan to offer the test nationally, potentially broadening access as developers push for earlier detection and treatment. Experts warn that a positive pTau217 result is not a definitive diagnosis and must be interpreted alongside other data.

via CNN|
#alzheimers-disease#blood-test#fda-clearance
Roche bets on muscle-preserving obesity drug in Hanmi deal worth up to $2.3B
business11 days ago

Roche bets on muscle-preserving obesity drug in Hanmi deal worth up to $2.3B

Roche/Genentech struck a deal with Hanmi to license HM17321, a UCN2-based obesity drug aimed at promoting weight loss while preserving lean muscle, for $190 million upfront and up to $2.3 billion in milestones. Genentech will hold global rights outside Korea, with Hanmi advancing to Phase 1 before Roche leads later-stage development, as Roche expands its cardiometabolic lineup and explores applications in obesity, diabetes, and cardiovascular disease.

via Fierce Biotech|
#business#hanmi#hm17321
Trial drug aims to halt Alzheimer's before symptoms with monthly infusions
health1 month ago

Trial drug aims to halt Alzheimer's before symptoms with monthly infusions

A Roche-developed drug called trontinemab, a next-generation antibody given as monthly infusions, may remove brain plaques more effectively and could stop or prevent Alzheimer's before symptoms, with a landmark trial enrolling about 1,600 people aged 55+ at high risk and using blood biomarkers like p-tau217 to identify those most likely to benefit, while aiming to improve safety compared with earlier drugs such as lecanemab and donanemab.

via Daily Express|
#alzheimers#clinical-trial#dementia
Petrelintide Delivers Up to 10.7% Weight Loss in Zealand‑Roche Phase 2 Trial
biotech6 months ago

Petrelintide Delivers Up to 10.7% Weight Loss in Zealand‑Roche Phase 2 Trial

Zealand Pharma's Roche-partnered amylin analog petrelintide achieved statistically significant weight loss versus placebo in a 493-person phase 2 obesity trial (Zupreme-1), with up to 10.7% mean weight reduction at 42 weeks and a tolerable safety profile (no vomiting at the maximally effective dose; mild GI adverse events); the results support moving toward phase 3 (Zupreme-2) and related combination studies, though some analysts question its potential impact in a crowded obesity market, and the stock fell on the news.

via Fierce Biotech|
#biotech#obesity#petrelintide
AstraZeneca and Gilead Compete for Leadership in Triple-Negative Breast Cancer Treatments
healthcare10 months ago

AstraZeneca and Gilead Compete for Leadership in Triple-Negative Breast Cancer Treatments

Major pharmaceutical companies Gilead, AstraZeneca, and Roche reported promising new study results for cancer treatments, particularly in breast cancer, leading to stock price increases for Gilead and AstraZeneca, while Roche's shares declined slightly. The studies highlight advancements in drug efficacy and potential growth in the cancer drug market, with implications for future sales and industry competition.

via TipRanks|
#astrazeneca#breast-cancer#cancer
Roche Acquires Poseida for $1.5B, Boosting CAR-T Therapy Access
business1 year ago

Roche Acquires Poseida for $1.5B, Boosting CAR-T Therapy Access

Roche has agreed to acquire Poseida Therapeutics for $1.5 billion, integrating Poseida's CAR-T therapies and manufacturing capabilities into its Pharmaceuticals Division. The deal includes a tender offer for Poseida's shares at $9 each, with potential milestone payments. The acquisition, approved by both companies' boards, is expected to close in Q1 2025, enhancing Roche's cell therapy development in oncology, immunology, and neurology.

via Yahoo Finance|
#acquisition#business#car-t-therapies
Roche's Promising Weight Loss Pill Hits Eli Lilly, Novo Nordisk Shares
businesspharmaceuticals2 years ago

Roche's Promising Weight Loss Pill Hits Eli Lilly, Novo Nordisk Shares

Eli Lilly and Novo Nordisk stocks fell after Roche's Genentech unit reported positive early-stage data for its oral weight-loss drug, CT-996, which led to 6% weight loss in four weeks. This new development poses competition to Eli Lilly and Novo Nordisk's injectable treatments. Viking Therapeutics and Amgen, also developing oral weight-loss drugs, saw their stocks decline as well.

via Investor's Business Daily|
#businesspharmaceuticals#eli-lilly#novo-nordisk
"Roche's New Obesity Drug Shakes Up Market with Promising Trial Results"
business2 years ago

"Roche's New Obesity Drug Shakes Up Market with Promising Trial Results"

Shares of Novo Nordisk and Eli Lilly fell after Roche announced promising early-stage trial data for its new obesity drug candidate, CT-996, which showed significant weight loss in obese patients. Roche's shares rose, while other companies in the obesity treatment market, including Zealand Pharma, also saw declines. Roche's new drug could offer a competitive alternative to injectable treatments, though it may take years to become widely available.

via CNBC|
#business#eli-lilly#novo-nordisk
"FDA Advisory Committee Reviewing Alzheimer's Therapy Donanemab Amid Approval Delays and Treatment Battle"
health2 years ago

"FDA Advisory Committee Reviewing Alzheimer's Therapy Donanemab Amid Approval Delays and Treatment Battle"

Eli Lilly's Alzheimer's treatment, donanemab, faces setbacks as the FDA delays its approval decision and plans to hold an advisory committee meeting to discuss the drug. Competitors like Biogen and Roche are also making strides in Alzheimer's treatments, with a focus on under-the-skin shots and precision medicine. Despite the setbacks, experts believe it's an exciting time in the fight against Alzheimer's disease, with unprecedented diversity in Phase 3 clinical trials offering hope for more treatment options. However, challenges remain, including safety concerns and the need for more personalized approaches to treatment.

via Investor's Business Daily|
#alzheimers#biogen#eli-lilly
"Unveiling Final Fantasy 7 Rebirth: Characters, Features, and Updates"
gaming2 years ago

"Unveiling Final Fantasy 7 Rebirth: Characters, Features, and Updates"

The latest trailer for Final Fantasy 7 Rebirth confirms the return of Roche, a standout character from the Remake, hinting at a more expanded role for the elite SOLDIER forces and potentially adding new story elements for Rufus Shinra. The inclusion of Roche and other characters from the Remake trilogy in Rebirth reinforces the idea of a cohesive experience split into a trilogy, with the game set to release on February 29 for PlayStation 5.

via Inverse|
#final-fantasy-7#gaming#playstation-5